Reports - Neurodiagnostics Market
HealthcareNeurodiagnostics Market
Neurodiagnostics Market: Solutions, Growth & Trends | 2025-2035 by Product (Diagnostic and Imaging Systems, Electroencephalogram (EEG) Systems, Electromyography (EMG) Products, Magnetic Resonance Imaging (MRI) Systems, Ultrasound Imaging Systems, Computed Tomography (Ct) Scanner, Magnetoencephalogram (Meg) System, Position Emission Tomography (Pet) System, Angiography System, Other Systems, Clinical Testing Instruments, PCR, Next-Generation Sequencing (NGS), Sanger Sequencing, Other Clinical Diagnostic Products, Reagents & Consumables, Media and Serra, Solvents, Enzymes, Protein & Peptides, Probes, Buffers, Antibodies, Other Reagents) by Condition (Neuro Degenerative Diseases, Epilepsy, Stroke, Headache Disorders, Sleep Disorders, Other Diseases) by End User (Hospitals and Surgery Centers, Neurology Centers, Ambulatory Care Centers, Diagnostic Laboratories & Imaging Centers, Research Laboratories & Academic Institutes) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Industry Leaders Trust Us For Actionable Intelligence
Table of Contents
Chapter 1 Executive Dashboard
1. Strategic Imperatives
Chapter 2 Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Chapter 3 Global Neurodiagnostics Market - Segment Analysis
1. Overview
2. Global Neurodiagnostics Market, 2021 - 2034 (USD Million)
3. Global Neurodiagnostics Market - by Product
3.1. By Diagnostic and Imaging Systems
3.2. By Electroencephalogram (EEG) Systems
3.3. By Electromyography (EMG) Products
3.4. By Magnetic Resonance Imaging (MRI) Systems
3.5. By Ultrasound Imaging Systems
3.6. By Computed Tomography (Ct) Scanner
3.7. By Magnetoencephalogram (Meg) System
3.8. By Position Emission Tomography (Pet) System
3.9. By Angiography System
3.10. By Other Systems
3.11. By Clinical Testing Instruments
3.12. By PCR
3.13. By Next-Generation Sequencing (NGS)
3.14. By Sanger Sequencing
3.15. By Other Clinical Diagnostic Products
3.16. By Reagents & Consumables
3.17. By Media and Serra
3.18. By Solvents
3.19. By Enzymes, Protein & Peptides
3.20. By Probes
3.21. By Buffers
3.22. By Antibodies
3.23. By Other Reagents
4. Global Neurodiagnostics Market - by Condition
4.1. By Neuro Degenerative Diseases
4.2. By Epilepsy
4.3. By Stroke
4.4. By Headache Disorders
4.5. By Sleep Disorders
4.6. By Other Diseases
5. Global Neurodiagnostics Market - by End User
5.1. By Hospitals and Surgery Centers
5.2. By Neurology Centers
5.3. By Ambulatory Care Centers
5.4. By Diagnostic Laboratories & Imaging Centers
5.5. By Research Laboratories & Academic Institutes
6. Global Neurodiagnostics Market - by region
6.1. North America
6.2. Europe
6.3. Asia Pacific
6.4. Latin America
6.5. Middle East & Africa
7. Market comparative analysis
Chapter 4 North America Neurodiagnostics Market - Segment Analysis
1. Overview
2. North America Neurodiagnostics Market, 2021 - 2034 (USD Million)
3. North America Neurodiagnostics Market - by Product
3.1. By Diagnostic and Imaging Systems
3.2. By Electroencephalogram (EEG) Systems
3.3. By Electromyography (EMG) Products
3.4. By Magnetic Resonance Imaging (MRI) Systems
3.5. By Ultrasound Imaging Systems
3.6. By Computed Tomography (Ct) Scanner
3.7. By Magnetoencephalogram (Meg) System
3.8. By Position Emission Tomography (Pet) System
3.9. By Angiography System
3.10. By Other Systems
3.11. By Clinical Testing Instruments
3.12. By PCR
3.13. By Next-Generation Sequencing (NGS)
3.14. By Sanger Sequencing
3.15. By Other Clinical Diagnostic Products
3.16. By Reagents & Consumables
3.17. By Media and Serra
3.18. By Solvents
3.19. By Enzymes, Protein & Peptides
3.20. By Probes
3.21. By Buffers
3.22. By Antibodies
3.23. By Other Reagents
4. North America Neurodiagnostics Market - by Condition
4.1. By Neuro Degenerative Diseases
4.2. By Epilepsy
4.3. By Stroke
4.4. By Headache Disorders
4.5. By Sleep Disorders
4.6. By Other Diseases
5. North America Neurodiagnostics Market - by End User
5.1. By Hospitals and Surgery Centers
5.2. By Neurology Centers
5.3. By Ambulatory Care Centers
5.4. By Diagnostic Laboratories & Imaging Centers
5.5. By Research Laboratories & Academic Institutes
Chapter 5 Europe Neurodiagnostics Market - Segment Analysis
1. Overview
2. Europe Neurodiagnostics Market, 2021 - 2034 (USD Million)
3. Europe Neurodiagnostics Market - by Product
3.1. By Diagnostic and Imaging Systems
3.2. By Electroencephalogram (EEG) Systems
3.3. By Electromyography (EMG) Products
3.4. By Magnetic Resonance Imaging (MRI) Systems
3.5. By Ultrasound Imaging Systems
3.6. By Computed Tomography (Ct) Scanner
3.7. By Magnetoencephalogram (Meg) System
3.8. By Position Emission Tomography (Pet) System
3.9. By Angiography System
3.10. By Other Systems
3.11. By Clinical Testing Instruments
3.12. By PCR
3.13. By Next-Generation Sequencing (NGS)
3.14. By Sanger Sequencing
3.15. By Other Clinical Diagnostic Products
3.16. By Reagents & Consumables
3.17. By Media and Serra
3.18. By Solvents
3.19. By Enzymes, Protein & Peptides
3.20. By Probes
3.21. By Buffers
3.22. By Antibodies
3.23. By Other Reagents
4. Europe Neurodiagnostics Market - by Condition
4.1. By Neuro Degenerative Diseases
4.2. By Epilepsy
4.3. By Stroke
4.4. By Headache Disorders
4.5. By Sleep Disorders
4.6. By Other Diseases
5. Europe Neurodiagnostics Market - by End User
5.1. By Hospitals and Surgery Centers
5.2. By Neurology Centers
5.3. By Ambulatory Care Centers
5.4. By Diagnostic Laboratories & Imaging Centers
5.5. By Research Laboratories & Academic Institutes
Chapter 6 Asia Pacific Neurodiagnostics Market - Segment Analysis
1. Overview
2. Asia Pacific Neurodiagnostics Market, 2021 - 2034 (USD Million)
3. Asia Pacific Neurodiagnostics Market - by Product
3.1. By Diagnostic and Imaging Systems
3.2. By Electroencephalogram (EEG) Systems
3.3. By Electromyography (EMG) Products
3.4. By Magnetic Resonance Imaging (MRI) Systems
3.5. By Ultrasound Imaging Systems
3.6. By Computed Tomography (Ct) Scanner
3.7. By Magnetoencephalogram (Meg) System
3.8. By Position Emission Tomography (Pet) System
3.9. By Angiography System
3.10. By Other Systems
3.11. By Clinical Testing Instruments
3.12. By PCR
3.13. By Next-Generation Sequencing (NGS)
3.14. By Sanger Sequencing
3.15. By Other Clinical Diagnostic Products
3.16. By Reagents & Consumables
3.17. By Media and Serra
3.18. By Solvents
3.19. By Enzymes, Protein & Peptides
3.20. By Probes
3.21. By Buffers
3.22. By Antibodies
3.23. By Other Reagents
4. Asia Pacific Neurodiagnostics Market - by Condition
4.1. By Neuro Degenerative Diseases
4.2. By Epilepsy
4.3. By Stroke
4.4. By Headache Disorders
4.5. By Sleep Disorders
4.6. By Other Diseases
5. Asia Pacific Neurodiagnostics Market - by End User
5.1. By Hospitals and Surgery Centers
5.2. By Neurology Centers
5.3. By Ambulatory Care Centers
5.4. By Diagnostic Laboratories & Imaging Centers
5.5. By Research Laboratories & Academic Institutes
Chapter 7 Latin America Neurodiagnostics Market - Segment Analysis
1. Overview
2. Latin America Neurodiagnostics Market, 2021 - 2034 (USD Million)
3. Latin America Neurodiagnostics Market - by Product
3.1. By Diagnostic and Imaging Systems
3.2. By Electroencephalogram (EEG) Systems
3.3. By Electromyography (EMG) Products
3.4. By Magnetic Resonance Imaging (MRI) Systems
3.5. By Ultrasound Imaging Systems
3.6. By Computed Tomography (Ct) Scanner
3.7. By Magnetoencephalogram (Meg) System
3.8. By Position Emission Tomography (Pet) System
3.9. By Angiography System
3.10. By Other Systems
3.11. By Clinical Testing Instruments
3.12. By PCR
3.13. By Next-Generation Sequencing (NGS)
3.14. By Sanger Sequencing
3.15. By Other Clinical Diagnostic Products
3.16. By Reagents & Consumables
3.17. By Media and Serra
3.18. By Solvents
3.19. By Enzymes, Protein & Peptides
3.20. By Probes
3.21. By Buffers
3.22. By Antibodies
3.23. By Other Reagents
4. Latin America Neurodiagnostics Market - by Condition
4.1. By Neuro Degenerative Diseases
4.2. By Epilepsy
4.3. By Stroke
4.4. By Headache Disorders
4.5. By Sleep Disorders
4.6. By Other Diseases
5. Latin America Neurodiagnostics Market - by End User
5.1. By Hospitals and Surgery Centers
5.2. By Neurology Centers
5.3. By Ambulatory Care Centers
5.4. By Diagnostic Laboratories & Imaging Centers
5.5. By Research Laboratories & Academic Institutes
Chapter 8 Middle East & Africa Neurodiagnostics Market - Segment Analysis
1. Overview
2. Middle East & Africa Neurodiagnostics Market, 2021 - 2034 (USD Million)
3. Middle East & Africa Neurodiagnostics Market - by Product
3.1. By Diagnostic and Imaging Systems
3.2. By Electroencephalogram (EEG) Systems
3.3. By Electromyography (EMG) Products
3.4. By Magnetic Resonance Imaging (MRI) Systems
3.5. By Ultrasound Imaging Systems
3.6. By Computed Tomography (Ct) Scanner
3.7. By Magnetoencephalogram (Meg) System
3.8. By Position Emission Tomography (Pet) System
3.9. By Angiography System
3.10. By Other Systems
3.11. By Clinical Testing Instruments
3.12. By PCR
3.13. By Next-Generation Sequencing (NGS)
3.14. By Sanger Sequencing
3.15. By Other Clinical Diagnostic Products
3.16. By Reagents & Consumables
3.17. By Media and Serra
3.18. By Solvents
3.19. By Enzymes, Protein & Peptides
3.20. By Probes
3.21. By Buffers
3.22. By Antibodies
3.23. By Other Reagents
4. Middle East & Africa Neurodiagnostics Market - by Condition
4.1. By Neuro Degenerative Diseases
4.2. By Epilepsy
4.3. By Stroke
4.4. By Headache Disorders
4.5. By Sleep Disorders
4.6. By Other Diseases
5. Middle East & Africa Neurodiagnostics Market - by End User
5.1. By Hospitals and Surgery Centers
5.2. By Neurology Centers
5.3. By Ambulatory Care Centers
5.4. By Diagnostic Laboratories & Imaging Centers
5.5. By Research Laboratories & Academic Institutes
Chapter 9 Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
Chapter 10 COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Chapter 11 Marketing Strategy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Chapter 12 Competitive Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Chapter 13 Company Profiles
1. GE Healthcare (US)
2. Siemens Healthiness (Germany)
3. Philips Healthcare (Netherlands)
4. Canon Inc. (Japan)
5. Hitachi Ltd. (Japan)
6. Lifelines Neuro Company
7. LLC (US)
8. Natus Medical Incorporated (US)
9. Hoffman-La Roche AG (Switzerland)
10. FUJIFILM Holdings Corporation (Japan)
11. Mitsar Co. Ltd. (Russia)
12. Advanced Brain Monitoring (US)
13. Thermo Fisher Scientific Inc. (US)
14. Bio-Rad Laboratories (US)
15. QIAGEN N.V. (Netherlands)
16. and Nihon Kohden Corporation (Japan)
Chapter 14 Key Primary Respondents - VERBATIM
Chapter 15 Discussion Guide
Chapter 16 Customization Offered
Chapter 17 Annexure
Chapter 18 List of Figures
Chapter 19 List of Tables
Chapter 20 List of Abbreviations
FAQ‘s
Related Reports
Contact
Toll Free Number+1 (877) 462-2282
© 2025 Vantage Market Research. All right reserved
Secured By